JPH07278004A - Production of red blood coagulant factor - Google Patents

Production of red blood coagulant factor

Info

Publication number
JPH07278004A
JPH07278004A JP6085600A JP8560094A JPH07278004A JP H07278004 A JPH07278004 A JP H07278004A JP 6085600 A JP6085600 A JP 6085600A JP 8560094 A JP8560094 A JP 8560094A JP H07278004 A JPH07278004 A JP H07278004A
Authority
JP
Japan
Prior art keywords
activity
fraction
red blood
hemagglutinin
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP6085600A
Other languages
Japanese (ja)
Other versions
JP2723169B2 (en
Inventor
Hirotaka Kakita
浩孝 垣田
Satoshi Fukuoka
聰 福岡
Hideki Obika
秀樹 小比賀
Tadatomi Ri
忠富 李
Hiroshi Ueshima
洋 上嶋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Institute of Advanced Industrial Science and Technology AIST
Original Assignee
Agency of Industrial Science and Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency of Industrial Science and Technology filed Critical Agency of Industrial Science and Technology
Priority to JP6085600A priority Critical patent/JP2723169B2/en
Publication of JPH07278004A publication Critical patent/JPH07278004A/en
Application granted granted Critical
Publication of JP2723169B2 publication Critical patent/JP2723169B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)

Abstract

PURPOSE:To provide a production of a new red blood coagulant originating from a marine plant where its coagulation activity is high and can be controlled by the ionic strength with excellent selectivity in saccharide chain recognition. CONSTITUTION:A red algae, Gracilaria sp., is extracted with a phosphate buffer solution and the extract is salted out to obtain a rough active fraction, then the fraction is subjected to chromatography to separate the fraction of more than 100,000 molecular weight whereby the objective coagulant factor is obtained.

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【産業上の利用分野】本発明は、オゴノリ属紅藻類(G
racilaria sp.)を原料として、特異的な
性質をもつ新規な赤血球凝集素を製造する方法に関する
ものである。
BACKGROUND OF THE INVENTION The present invention relates to the red algae of the genus Ogonori (G.
racilaria sp. ) Is used as a raw material to produce a novel hemagglutinin having specific properties.

【0002】[0002]

【従来の技術】赤血球凝集素は、各動物の赤血球に対し
特異的な挙動を示すので、医療、製薬、生化学分野など
における検査用試薬や分離用材料として広く用いられて
いる。この赤血球凝集素は、動物由来のものと植物由来
のものとに大別されるが、大量に入手しうること、処理
しやすいことなどを考慮して、植物由来のものが実用上
注目されている。
2. Description of the Related Art Hemagglutinin, which exhibits specific behavior to erythrocytes of each animal, is widely used as a test reagent or a separation material in the fields of medicine, pharmaceuticals, biochemistry and the like. This hemagglutinin is roughly classified into animal-derived ones and plant-derived ones, but plant-derived ones have been attracting attention in practical use in consideration of availability in large quantities and easy processing. There is.

【0003】これまで、この植物由来の赤血球凝集素と
しては、陸上植物由来のものとしてタチナタマメからの
コンカナバリンA(Con A)や小麦からの小麦胚芽
レクチン(WGA)などや[「ジャーナル・オブ・バク
テリオロジー(J.Bacteriol.)」第32
巻、第227〜237ページ(1936年)]、海洋植
物由来のものとしてオゴノリ(Gracilaria
verrucosa)からのGVAI、カギイバラノリ
(Hypnea japonica)からのHypni
n A、B、C及びD[「ブレタン・オブ・ザ・ジャパ
ニーズ・ソサエティ・オブ・サイエンティフィック・フ
ィッシェリイズ(Bul.Jap.Soc.Sci.F
ishe.)」第47巻、第1079〜1084ページ
(1981年)]などが知られている。
So far, as the hemagglutinin derived from this plant, concanavalin A (Con A) from jack bean and wheat germ lectin (WGA) from wheat as derived from land plants and [[Journal of Bacterio 32. J. Bacteriol.
Vol. 227-237 (1936)], as a source of marine plants (Gracilaria)
GVAI from Verrucosa), Hypni from Hypnea japonica
n A, B, C and D ["Bret. of the Japanese Society of Scientific Fisheries (Bul.Jap.Soc.Sci.F.
ise. ) ”, Vol. 47, pp. 1079-1084 (1981)] and the like.

【0004】しかしながら、陸上植物由来のものは、凝
集活性の高い標品は比較的容易に得ることができる
が、、単糖類や二糖類のような単純な糖によっても赤血
球凝集活性が阻害されるため、認識糖鎖選択性が低いと
いう欠点があるし、また海洋植物由来のものは、単糖類
や二糖類によって赤血球凝集活性が阻害されず、フェツ
イン、アシアロフェツインのような糖タンパク質によっ
て阻害されるため、認識糖鎖選択性が高いと考えられる
が、凝集活性の高い標品を得ることが困難であるという
欠点を有する上に、両者ともイオン強度の変化により凝
集活性の制御を行うことができないという欠点をもって
いる。
[0004] However, although a preparation having a high agglutinating activity can be obtained relatively easily from a plant derived from a land plant, the hemagglutination activity is inhibited by a simple sugar such as a monosaccharide or a disaccharide. Therefore, it has the disadvantage that the recognition sugar chain selectivity is low, and that those derived from marine plants are not inhibited by hemagglutination activity by monosaccharides and disaccharides, but by glycoproteins such as fetuin and asialofetuin. Therefore, it is considered that the recognition sugar chain selectivity is high, but it has the drawback that it is difficult to obtain a preparation with high agglutination activity, and both can control agglutination activity by changing the ionic strength. It has the drawback of not being able to.

【0005】[0005]

【発明が解決しようとする課題】本発明は、このような
事情のもとで、イオン強度により凝集活性が制御でき、
認識糖鎖選択性に優れ、かつ比活性が高い新規な赤血球
凝集素を提供することを目的としてなされたものであ
る。
Under the above circumstances, the present invention can control the agglutination activity by the ionic strength,
The purpose of the present invention is to provide a novel hemagglutinin having excellent recognition sugar chain selectivity and high specific activity.

【0006】[0006]

【課題を解決するための手段】本発明者らは、植物由
来、特に海洋植物由来の赤血球凝集素について、種々研
究を重ねた結果、オゴノリ属紅藻類(Gracilar
ia sp.)から、特定な条件下で抽出された赤血球
凝集素が、凝集活性が高く認識糖類選択性が高い上に、
イオン強度により凝集活性を制御しうることを見出し、
この知見に基づいて本発明をなすに至った。
[Means for Solving the Problems] The inventors of the present invention have conducted various studies on hemagglutinins derived from plants, particularly marine plants, and as a result, have found that the red algae of the genus Gragonar
ia sp. ), Hemagglutinin extracted under specific conditions has high aggregation activity and high recognition saccharide selectivity, and
It was found that the aggregation activity can be controlled by the ionic strength,
The present invention has been completed based on this finding.

【0007】すなわち、本発明は、オゴノリ属紅藻類
(Gracilaria sp.)からのリン酸塩緩衝
液抽出液を、塩析して粗活性画分を分取し、次いでクロ
マトグラフィーにより分子量100,000以上の画分
を分離、回収することを特徴とする赤血球凝集素の製造
方法を提供するものである。
That is, according to the present invention, a phosphate buffer extract from red seaweed (Gracilaria sp.) Is salted out to collect a crude active fraction, followed by chromatography to obtain a molecular weight of 100,000. The present invention provides a method for producing hemagglutinin, which comprises separating and collecting the above fractions.

【0008】本発明方法における原料としては、オゴノ
リ属紅藻類が用いられるが、特にオゴノリ(Graci
laria verrucosa)、ツルシラモ(Gr
acilaria chorda)、それらの亜種が好
ましい。これらの紅藻類は、寒海にも存在するが特に暖
海に多く、わが国ではほとんどすべての海岸地帯に分布
しており、寒天の増量物や刺身のつまなどに用いられて
いる。
As a raw material in the method of the present invention, red algae of the genus Ogonori are used.
laria verrucosa), tsurcilamo (Gr
acilaria chorda), variants thereof are preferred. These red algae are also found in the cold sea, but especially in the warm sea, and they are distributed in almost all coastal areas in Japan, and they are used as agar extenders and sashimi bites.

【0009】本発明方法に従えば、上記の紅藻類原料に
(イ)水溶性画分の抽出工程、(ロ)粗活性画分の分取
工程、及び(ハ)凝集素の精製工程を順次施すことによ
り、所望の赤血球凝集素を得ることができる。
According to the method of the present invention, the above red algae raw material is sequentially subjected to (a) a water-soluble fraction extraction step, (b) a crude active fraction fractionation step, and (c) an agglutinin purification step. By applying it, a desired hemagglutinin can be obtained.

【0010】前記各工程の好適な実施態様について説明
すると、まず(イ)工程においては、原料の紅藻類に緩
衝液、例えば塩化ナトリウム含有リン酸緩衝液を加えて
ホモゲナイズしたのち、遠心分離処理し、上澄である粗
抽出液を得る。次に(ロ)工程においては、前記(イ)
工程で得られた抽出液に、まず最終濃度が30〜40重
量%程度の飽和溶液になるように硫酸アンモニウムを加
えて1段目の塩析を行い、生成した沈殿を遠心分離処理
により除去する。この操作で色素などの夾雑物が沈殿画
分として除去される。次いで、遠心分離処理で得た上澄
に最終濃度70重量%程度の飽和溶液になるように硫酸
アンモニウムを加えて2段目の塩析を行い、生成した沈
殿を遠心分離処理により分別したのち、この沈殿画分を
塩化ナトリウム含有リン酸緩衝液などの緩衝液で再溶解
して粗活性画分を得る。
Explaining preferred embodiments of each of the above-mentioned steps, first, in the step (a), a buffer solution, for example, a sodium chloride-containing phosphate buffer solution is added to the starting red algae to homogenize it, followed by centrifugation. , A crude extract which is a supernatant is obtained. Next, in the step (b), the above (a)
First, ammonium sulfate is added to the extract obtained in the step so that the final concentration is a saturated solution of about 30 to 40% by weight, salting out in the first step is performed, and the formed precipitate is removed by centrifugation. By this operation, contaminants such as pigments are removed as a precipitate fraction. Then, ammonium sulphate was added to the supernatant obtained by centrifugation to add a saturated solution having a final concentration of about 70% by weight, and salting out was carried out in the second step. The precipitated fraction is redissolved in a buffer solution such as sodium chloride-containing phosphate buffer solution to obtain a crude active fraction.

【0011】最後に、(ハ)工程においては、前記
(ロ)工程で得られた粗活性画分を、塩化ナトリウム含
有リン酸緩衝液などの緩衝液に対して透析後、クロマト
グラフィーにより分離し、精製赤血球凝集素を得る。こ
の際、クロマトグラフィーとしては、イオン交換クロマ
トグラフィー又はゲルろ過クロマトグラフィーあるいは
それらの組合せが好ましく用いられる。
Finally, in the step (c), the crude active fraction obtained in the step (b) is dialyzed against a buffer solution such as a sodium chloride-containing phosphate buffer solution and then separated by chromatography. , To obtain purified hemagglutinin. At this time, as the chromatography, ion exchange chromatography, gel filtration chromatography or a combination thereof is preferably used.

【0012】本発明方法で得られる赤血球凝集素は、新
規物質で(a)プロナーゼ処理したヒツジ赤血球を凝集
させる性質を有し、かつこの凝集活性が単純な単糖類又
は二糖類では阻害されないが、フェツインやアシアロフ
ェツインのような糖タンパク質で阻害され、(b)ウサ
ギ赤血球に対する凝集活性がイオン強度により変化し、
かつ(c)球状タンパク質を標準分子量物質として使用
したときのゲルろ過クロマトグラフィーにおいて、分子
量100,000以上に相当する画分に溶出するという
特徴を有している。
The hemagglutinin obtained by the method of the present invention has the property of aggregating sheep red blood cells treated with (a) pronase with a novel substance, and this agglutination activity is not inhibited by simple monosaccharides or disaccharides. Inhibited by glycoproteins such as fetuin and asialofetuin, (b) the agglutination activity on rabbit red blood cells changes with ionic strength,
In addition, in (c) the globular protein is used as a standard molecular weight substance, it has a characteristic of being eluted in a fraction corresponding to a molecular weight of 100,000 or more in gel filtration chromatography.

【0013】[0013]

【発明の効果】本発明方法により得られる赤血球凝集素
は、紅藻類由来の新規なものであって、イオン強度によ
り凝集活性が制御でき、認識糖鎖選択性に優れ、かつ比
活性が高いなどの特性を有している。この特性を利用す
れば、イオン強度により、凝集素の凝集活性を制御する
ことができるため、臨床分野、医療分野、生化学工業分
野などにおいて、例えば検査用試薬や分離材料などとし
て使用することができる。
EFFECTS OF THE INVENTION The hemagglutinin obtained by the method of the present invention is a novel one derived from red algae, and the agglutination activity can be controlled by ionic strength, the recognition sugar chain selectivity is excellent, and the specific activity is high. It has the characteristics of If this property is utilized, the aggregating activity of agglutinin can be controlled by the ionic strength, so that it can be used as a test reagent or a separation material in the clinical field, medical field, biochemical industry field, etc. it can.

【0014】[0014]

【実施例】次に、実施例により本発明をさらに詳細に説
明するが、本発明はこれらの例によってなんら限定され
るものではない。
The present invention will be described in more detail by way of examples, which should not be construed as limiting the invention thereto.

【0015】実施例1 (イ)水溶性画分の抽出工程 ツルシラモ(徳島県吉野川河口域産)を0.15M塩化
ナトリウム水溶液で洗浄後、天日乾燥して乾燥物を得
た。この乾燥物100gに0.15M塩化ナトリウム含
有100mMリン酸緩衝液(pH6.9)700mlを
加えてホモゲナイズしたのち、このホモゲナイズした液
を4℃で6時間放置後、遠心分離して上澄である粗抽出
液を得た。
Example 1 (a) Extraction Step of Water-Soluble Fraction Tsurushiramo (produced by Yoshino River estuary in Tokushima Prefecture) was washed with 0.15M sodium chloride aqueous solution and dried in the sun to obtain a dried product. After homogenizing by adding 700 ml of 0.15 M sodium chloride-containing 100 mM phosphate buffer (pH 6.9) to 100 g of this dried product, the homogenized solution was left standing at 4 ° C. for 6 hours and then centrifuged to obtain a supernatant. A crude extract was obtained.

【0016】(ロ)粗活性画分の分別工程 次いで、この粗抽出液に、最終濃度35重量%飽和溶液
になるように硫酸アンモニウムを加えて1段目の塩析を
行った。硫酸アンモニウムを添加終了後、4℃で1時間
放置したのち、生成した沈殿を遠心分離して除去した。
この操作で色素などの夾雑物が沈殿画分として除去され
た。次に、遠心分離で得た上澄に、最終濃度70重量%
飽和溶液になるように硫酸アンモニウムを加えて2段目
の塩析を行った。硫酸アンモニウムを添加終了後、4℃
で一晩放置したのち、生成した沈殿を遠心分離して分別
した。分別した沈殿画分を、0.15M塩化ナトリウム
含有100mMリン酸緩衝液(pH6.9)で再溶解
し、粗活性画分を得た。得られた粗活性画分のウサギ赤
血球に対する赤血球凝集活性は256単位であり、比活
性は3372.9単位/mgプロテイン、活性回収率は
62.4%であった。ここで、凝集活性の単位は、凝集
活性が検出できる試料の最大希釈率の逆数と定義した。
これらの結果を表1に示す。
(B) Fractionation step of crude active fraction Next, ammonium sulfate was added to this crude extract so that the final concentration was 35% by weight, and salting out was carried out in the first step. After the addition of ammonium sulfate was completed, the mixture was allowed to stand at 4 ° C. for 1 hour, and then the generated precipitate was removed by centrifugation.
By this operation, contaminants such as pigments were removed as a precipitate fraction. Then, the supernatant obtained by centrifugation was added to a final concentration of 70% by weight.
Ammonium sulfate was added so that the solution became a saturated solution, and second-stage salting out was performed. After adding ammonium sulfate, 4 ℃
After being left overnight at, the generated precipitate was separated by centrifugation. The separated precipitation fraction was redissolved in a 0.15 M sodium chloride-containing 100 mM phosphate buffer (pH 6.9) to obtain a crude active fraction. The hemagglutination activity of the obtained crude active fraction on rabbit red blood cells was 256 units, the specific activity was 3372.9 units / mg protein, and the activity recovery rate was 62.4%. Here, the unit of the agglutination activity was defined as the reciprocal of the maximum dilution rate of the sample in which the agglutination activity can be detected.
The results are shown in Table 1.

【0017】(ハ)凝集素の精製工程 次に、このようにして得られた粗活性画分を、0.15
M塩化ナトリウム含有100mMリン酸緩衝液(pH
6.9)に対して透析後、TSKgelDEAE‐5P
Wを用いたイオン交換クロマトグラフィーにより分離
し、精製標品を得た。得られた精製標品のウサギ赤血球
に対する赤血球凝集活性を示す最小タンパク質濃度は
0.8763μg/mlであった。以上の結果から、本
発明方法によると、紅藻類由来の赤血球凝集素が、その
活性を保持したまま効果的に得られることが分かる。
(C) Step of purifying agglutinin Next, the crude active fraction thus obtained was treated with 0.15
100 mM phosphate buffer containing M sodium chloride (pH
After dialysis against 6.9), TSKgel DEAE-5P
Separation was carried out by ion exchange chromatography using W to obtain a purified standard product. The minimum protein concentration of the obtained purified sample showing hemagglutination activity against rabbit red blood cells was 0.8763 μg / ml. From the above results, it is understood that according to the method of the present invention, hemagglutinin derived from red algae can be effectively obtained while maintaining its activity.

【0018】精製標品について、ウサギ赤血球に対する
凝集活性のイオン強度依存性を検討したところ、0.1
5M塩化ナトリウム濃度での凝集活性は2048単位で
あり、一方0.4M塩化ナトリウム濃度での凝集活性は
8単位であった。これらの結果を表2に示す。
The ionic strength dependence of the agglutinating activity on rabbit red blood cells of the purified preparation was examined.
The aggregation activity at a concentration of 5M sodium chloride was 2048 units, while the aggregation activity at a concentration of 0.4M sodium chloride was 8 units. The results are shown in Table 2.

【0019】比較例1 実施例1‐(ロ)の粗活性画分の分別工程において、硫
酸アンモニウム添加による2段階の塩析による分別処理
の代わりに、50重量%エタノールによる分別処理
[「フィトケミストリー(Phytochemistr
y)」第27巻、第2063〜2067ページ(198
8年)参照]を行った以外は、実施例1と同様にして粗
活性画分を得た。この粗活性画分のウサギ赤血球に対す
る赤血球凝集活性は4単位、比活性は53.4単位/m
gプロテイン、活性回収率は5.0%であった。これら
の結果を表1に示す。
Comparative Example 1 In the fractionation step of the crude active fraction of Example 1- (b), instead of the fractionation treatment by salting out in two steps by addition of ammonium sulfate, fractionation treatment with 50 wt% ethanol [“phytochemistry ( Phytochemistr
y) '' Vol. 27, pp. 2063-2067 (198)
8 years))] was carried out, and a crude active fraction was obtained in the same manner as in Example 1. This crude active fraction had a hemagglutination activity of 4 units against rabbit erythrocytes and a specific activity of 53.4 units / m 2.
The g protein and activity recovery was 5.0%. The results are shown in Table 1.

【0020】比較例2 「Comp.Biochem.Physiol.」第1
02B巻、第445〜449ページ(1992年)に記
載されている方法に従って、紅藻類由来の赤血球凝集素
を得た。得られた粗活性画分の赤血球凝集活性は16単
位、比活性は149.5単位/mgプロテイン、活性回
収率は19.5%であった。これらの結果を表1に示
す。また、精製標品のウサギ赤血球に対する赤血球凝集
活性を示す最小タンパク質濃度は32.6μg/mlで
あり、実施例1の約1/40の比活性に相当した。
Comparative Example 2 "Comp. Biochem. Physiol." No. 1
Hemagglutinin from red algae was obtained according to the method described in Vol. 02B, pp. 445-449 (1992). The resulting crude active fraction had a hemagglutination activity of 16 units, a specific activity of 149.5 units / mg protein, and an activity recovery rate of 19.5%. The results are shown in Table 1. In addition, the minimum protein concentration showing the hemagglutination activity of the purified preparation against rabbit red blood cells was 32.6 μg / ml, which was equivalent to the specific activity of about 1/40 of Example 1.

【0021】比較例3 紅藻類から「Comp.Biochem.Physio
l.」第102B巻、第445〜449ページ(199
2年)記載の方法に従って精製した分子量約50,00
0の凝集素について、ウサギ赤血球に対する凝集活性の
イオン濃度依存性を検討した。0.15M塩化ナトリウ
ム濃度及び0.4M塩化ナトリウム濃度での凝集活性は
ともに1024単位であり、凝集活性のイオン強度依存
性は見られなかった。これらの結果を表2に示す。
Comparative Example 3 From red algae, “Comp. Biochem. Physio
l. 102B, 445-449 (199
2 years) molecular weight of about 50,000 purified according to the method described
Regarding the agglutinin of 0, the ion concentration dependence of the agglutination activity on rabbit erythrocytes was examined. The aggregation activity at both 0.15 M sodium chloride concentration and 0.4 M sodium chloride concentration was 1024 units, and the ionic strength dependence of the aggregation activity was not seen. The results are shown in Table 2.

【0022】比較例4 Con A[和光純薬(株)製]25mgをリン酸緩衝
液100mlに溶解し、ウサギ赤血球に対する赤血球凝
集活性のイオン強度依存性を検討した。0.15M塩化
ナトリウム濃度及び0.4M塩化ナトリウム濃度での凝
集活性はともに64単位であり、凝集活性のイオン強度
依存性は見られなかった。これらの結果を表2に示す。
Comparative Example 4 25 mg of Con A [manufactured by Wako Pure Chemical Industries, Ltd.] was dissolved in 100 ml of phosphate buffer, and the ionic strength dependence of the hemagglutination activity on rabbit red blood cells was examined. The aggregation activity at both 0.15 M sodium chloride concentration and 0.4 M sodium chloride concentration was 64 units, and the ionic strength dependence of the aggregation activity was not observed. The results are shown in Table 2.

【0023】[0023]

【表1】 注1)凝集活性は粗活性画分を連続希釈し、凝集活性を
示す最大希釈率から算出した。 2)活性回収率は粗抽出液全量の凝集活性を100%と
して算出した。
[Table 1] Note 1) The agglutination activity was calculated from the maximum dilution rate showing agglutination activity by serially diluting the crude active fraction. 2) The activity recovery rate was calculated with the agglutinating activity of the entire crude extract as 100%.

【0024】[0024]

【表2】 注1)凝集活性は精製凝集素を連続希釈し、凝集活性を
示す最大希釈率から算出した。
[Table 2] Note 1) Agglutination activity was calculated from the maximum dilution rate showing agglutination activity after serially diluting purified agglutinin.

【0025】表1から明らかなように、実施例の粗活性
画分は、比較例1及び2のものに比べて、凝集活性、比
活性、活性回収率がともに高く、活性回収率は比較例1
の約12倍、比較例2の約3倍、比活性は比較例1の約
63倍、比較例2の約23倍である。また、表2から実
施例の精製凝集素は、比較例3及び4のものと異なり、
ウサギ赤血球に対する凝集活性がイオン強度により制御
されることが分かる。
As is clear from Table 1, the crude active fractions of Examples have higher aggregation activity, specific activity and activity recovery rate than those of Comparative Examples 1 and 2, and the activity recovery rates are comparative examples. 1
About 12 times, about 3 times that of Comparative Example 2, and the specific activity is about 63 times that of Comparative Example 1 and about 23 times that of Comparative Example 2. Further, from Table 2, the purified agglutinin of the Example is different from those of Comparative Examples 3 and 4,
It can be seen that the agglutination activity on rabbit red blood cells is controlled by ionic strength.

───────────────────────────────────────────────────── フロントページの続き (72)発明者 李 忠富 香川県高松市花ノ宮町二丁目3番3号 工 業技術院四国工業技術研究所内 (72)発明者 上嶋 洋 香川県高松市花ノ宮町二丁目3番3号 工 業技術院四国工業技術研究所内 ─────────────────────────────────────────────────── ─── Continuation of the front page (72) Inventor Lee Tadatomi 2-3-3 Hananomiya-cho, Takamatsu-shi, Kagawa Prefecture Shikoku Institute of Industrial Technology, Institute of Industrial Technology (72) Inventor Hiroshi Uejima Hananomiya-cho, Takamatsu-shi, Kagawa 3-3, Shikoku Institute of Industrial Technology, Institute of Industrial Technology

Claims (2)

【特許請求の範囲】[Claims] 【請求項1】 オゴノリ属紅藻類(Gracilari
a sp.)からのリン酸塩緩衝液抽出液を、塩析して
粗活性画分を分取し、次いでクロマトグラフィーにより
分子量100,000以上の画分を分離、回収すること
を特徴とする赤血球凝集素の製造方法。
1. A red alga, Gracilari
a sp. The salt solution of the phosphate buffer extract from the above) is subjected to salting out to collect a crude active fraction, and then a fraction having a molecular weight of 100,000 or more is separated and collected by chromatography to collect the hemagglutinin. Manufacturing method.
【請求項2】 オゴノリ属紅藻類がオゴノリ(Grac
ilaria verrucosa)又はツルシラモ
(Gracilaria chorda)あるいはそれ
らの亜種である請求項1記載の製造方法。
2. The red alga of the genus Ogonori belongs to
2. The production method according to claim 1, which is ilaria verrucosa) or tsurcilamo (Gracilaria chorda) or a subspecies thereof.
JP6085600A 1994-03-31 1994-03-31 Method for producing hemagglutinin Expired - Lifetime JP2723169B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP6085600A JP2723169B2 (en) 1994-03-31 1994-03-31 Method for producing hemagglutinin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP6085600A JP2723169B2 (en) 1994-03-31 1994-03-31 Method for producing hemagglutinin

Publications (2)

Publication Number Publication Date
JPH07278004A true JPH07278004A (en) 1995-10-24
JP2723169B2 JP2723169B2 (en) 1998-03-09

Family

ID=13863324

Family Applications (1)

Application Number Title Priority Date Filing Date
JP6085600A Expired - Lifetime JP2723169B2 (en) 1994-03-31 1994-03-31 Method for producing hemagglutinin

Country Status (1)

Country Link
JP (1) JP2723169B2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004087187A1 (en) * 2003-03-31 2004-10-14 National Institute Of Advanced Industrial Science And Technology Method of enhancing autoimmunity
JP2006272327A (en) * 2005-03-03 2006-10-12 National Institute Of Advanced Industrial & Technology Water obtained by reducing treatment of nutrient salt concentration in brine and method for producing the same

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03279396A (en) * 1990-03-29 1991-12-10 Agency Of Ind Science & Technol Rhodophyceae lectin and production thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03279396A (en) * 1990-03-29 1991-12-10 Agency Of Ind Science & Technol Rhodophyceae lectin and production thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004087187A1 (en) * 2003-03-31 2004-10-14 National Institute Of Advanced Industrial Science And Technology Method of enhancing autoimmunity
JP2006272327A (en) * 2005-03-03 2006-10-12 National Institute Of Advanced Industrial & Technology Water obtained by reducing treatment of nutrient salt concentration in brine and method for producing the same

Also Published As

Publication number Publication date
JP2723169B2 (en) 1998-03-09

Similar Documents

Publication Publication Date Title
CN101089021B (en) Process of separating and extracting hyaluronic acid from microbial fermented liquid
DE60307500T2 (en) POLYSACCHARIDE OF ECHINACEA ANGUSTIFOLIA
DE3019847A1 (en) METHOD FOR PRODUCING HUMAN INTERFERON AND MEANS CONTAINING IT
BR0215394B1 (en) Composition comprising aloe vera derivable polysaccharides, NAG-25 extract, ultrafiltered aloe extract, their preparation processes, their dosage forms, and their uses
DE1617805C3 (en) Process for obtaining lysozyme from protein
US5268366A (en) Polysaccharide composition or polysaccharide having heparinoid activity, process for producing the same, and anticoagulant containing the same as active ingredient
CN1412203A (en) Extraction separation method of algae polysaccharide
JP2723169B2 (en) Method for producing hemagglutinin
JP2001172296A (en) Method for purifying cartilage type proteoglycan
CN104004109B (en) Ocean Sulfation glycosaminoglycans SE-3 and preparation method thereof
DE60204967T2 (en) USE OF OVER-SULFATED POLYSACCHARIDES AS HIV HEMMER
US20060078569A1 (en) Method for recovery of photo-inhibited immunological activity
CN110627863B (en) Proteoglycan extraction method, proteoglycan extract, application of proteoglycan extract and cosmetic
Zhe-fu et al. Chitinases from seeds of Zea mays and Coix lachryma-jobi L. Purification and some properties
JP3041598B2 (en) Seaweed lectin and method for producing the same
WO1991004275A1 (en) New proteins suitable for combating disease and for protecting grazing cattle from ticks
Hickey Extraction and characterization of bioactive carbohydrates with health benefits from marine resources: macro-and microalgae, cyanobacteria, and invertebrates
JPH0245501A (en) Chikusetsu ginseng polysaccharide and use thereof
JPH03279396A (en) Rhodophyceae lectin and production thereof
JPH11290005A (en) Water-soluble propolis and its production
CN113528605B (en) Method for preparing urechis unicinctus viscera antioxidant peptide by ultrasonic-assisted enzymolysis
JP2004315520A (en) Autoimmunity potentiating agent, method for producing the same, and cosmetic by using the same
JP2895962B2 (en) Novel lectin and method for producing the same
DE4242813A1 (en)
JP4670077B2 (en) Method for purifying bioactive polymer substance and purified product obtained by the method

Legal Events

Date Code Title Description
EXPY Cancellation because of completion of term